# US 2021/0275620 A1 · Method and compositions for the use of botanical extracts in the treatment of viral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275620 A1
- Document ID: US20210275620A1
- Status: Published application
- Kind: A1
- Application number: 17/150,476
- Filed: 2021-01-15
- Published: 2021-09-09
- Earliest claimed: 2015-05-19
- Assignees: Aviratek Biomedical Solutions, LLC
- Applicants: Aviratek Biomedical Solutions, LLC
- Inventors: Jeffrey Langland; Karen Denzler; Robert Waters; Bertram Jacobs
- Web page: https://patentgrep.com/patent/US20210275620A1

## CPC

- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 36/254: Acanthopanax or Eleutherococcus
- A61K 36/38: Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
- A61K 36/484: Glycyrrhiza (licorice)
- A61K 36/68: Plantaginaceae (Plantain Family)
- A61K 36/88: Liliopsida (monocotyledons)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61K 2236/13: involving cleaning, e.g. washing or peeling
- A61K 2236/333: using mixed solvents, e.g. 70% EtOH
- A61K 2236/37: Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates generally to the preparation and use of certain botanical extracts and therapeutic compositions for the treatment of viral infections, cancer, pain, itch, and inflammation. The present disclosure generally relates to antiviral compositions, and more specifically to the preparation of botanical extracts and their use in the treatment of viral infections, cancer, pain associated conditions.

## Claims

### Claim 1

A method for inhibiting the replication of a herpesvirus by exposing the herpesvirus to an extract from a plant material chosen from Sarracenia, Nepenthes, Melissa, Lavandula, Glycyrrhiza, Eleutherococcus, Hypericum, Darlingtonia, Heliamphora, Roridula, Drosera, Dionaea, Aldrovanda, Drosophyllum, Triphyophyllum, Catopsis, Brocchinia, Paepalanthus, Utricularia, Genlisea, Pinguicula, Ibicella, Byblis, Philcoxia, Stylidium, and Cephalotus, wherein the plant material is prepared by steps comprising:
obtaining fresh plant material let than about ten (10) days following harvest of the plant material;
washing and air drying the plant material;
combining the plant material with a liquid comprising at least one of water, ethanol, and glycerol;
allowing the liquid to extract the plant material at a temperature between about room temperature and simmering for about one (1) to about sixty (60) days, or by boiling for less than about one day to form the liquid extract; and
separating the liquid extract from the plant material.

### Claim 2 (depends on 1)

The method of claim 1, wherein the plant material comprises leaves.

### Claim 3 (depends on 1)

The method of claim 1, wherein the plant material comprises roots.

### Claim 4 (depends on 1)

The method of claim 1, wherein the plant material comprises flowers.

### Claim 5 (depends on 1)

The method of claim 1, wherein the herpesvirus is selected from the group consisting of herpes simplex virus 1, herpes simplex virus 2, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, and human herpesvirus 8.

### Claim 6 (depends on 1)

The method of claim 1, wherein the herpesvirus is an animal herpesvirus.

### Claim 7 (depends on 6)

The method of claim 6, wherein the animal herpesvirus is equine herpesvirus-1.

### Claim 8 (depends on 1)

The method of claim 1, further comprising a step combining the liquid extract with a food-grade or pharmaceutically acceptable excipient to form a therapeutic composition.

### Claim 9 (depends on 8)

The method of claim 8, wherein the food-grade or pharmaceutically acceptable excipient is a transdermal-driving carrier/gel.

### Claim 10 (depends on 8)

The method of claim 8, wherein the therapeutic composition is applied to a mucosal ulceration.

### Claim 11 (depends on 8)

The method of claim 8, wherein the therapeutic composition is applied to a skin ulceration.

### Claim 12 (depends on 1)

The method of claim 1, further comprising a step creating a standardized assay with respect to the ability of the liquid extract to inhibit replication of the herpesvirus.

### Claim 13 (depends on 12)

The method of claim 12, wherein the liquid extract comprises:
about 50% of a liquid extract of Sarracenia purpurea having a biological activity of about fifty (50) viral inhibitory units per milliliter;
about 12% of a liquid extract of Melissa officinalis having a biological activity of about eighty (80) viral inhibitory units per milliliter; and
about 20% of a liquid extract of Lavandula officinalis having a biological activity of about twenty (20) viral inhibitory units per milliliter.

### Claim 14 (depends on 12)

The method of claim 12, wherein the liquid extract comprises:
about 50% of a liquid extract of Sarracenia purpurea having a biological activity of about fifty (50) viral inhibitory units per milliliter; and
an extract of the genus Nepenthes.

### Claim 15 (depends on 12)

The method of claim 12, wherein the herpesvirus is selected from the group consisting of herpes simplex virus 1, herpes simplex virus 2, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, and human herpesvirus 8.

### Claim 16 (depends on 12)

The method of claim 12, further comprising a step combining the liquid extract with a food-grade or pharmaceutically acceptable excipient to form a therapeutic composition.

### Claim 17

A method for prophylactic or therapeutic treatment of a human herpesvirus infection comprising exposing a human herpes virus to a therapeutic composition formed from a liquid extract of a plant material wherein the plant material is chosen from the group consisting of Sarracenia, Nepenthes, Melissa, Lavandula, Glycyrrhiza, Eleutherococcus, Hypericum, Darlingtonia, Heliamphora, Roridula, Drosera, Dionaea, Aldrovanda, Drosophyllum, Triphyophyllum, Catopsis, Brocchinia, Paepalanthus, Utricularia, Genlisea, Pinguicula, Ibicella, Byblis, Philcoxia, Stylidium, and Cephalotus.

### Claim 18 (depends on 17)

The method of claim 17, wherein the human herpes virus is herpes simplex virus-1.

### Claim 19 (depends on 17)

The method of claim 17, wherein the human herpes virus is herpes simplex virus-2.

### Claim 20 (depends on 17)

The method of claim 17, wherein the plant material comprises leaves, roots, or flowers.